Skip to main content
AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.92%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B+0.02%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA+0.07%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%1816.HK+3.45%HD+0.06%3988.HK-1.13%BAC+0.05%GE0.00%0857.HK-0.49%ORCL-0.01%UNH+0.02%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.14%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%GBPSGD0.00%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%CADJPY0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%CHFJPY0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%EURPLN0.00%NZDMXN0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+2.59%ETHUSD+77.41%USDTUSD+0.10%XRPUSD+64.83%SOLUSD+72.04%TRXUSDT+1.25%ZECUSDT+4.71%XMRUSDT+7.26%DOGEUSD+72.43%LINKUSD+1.21%XLMUSD+1.89%BCHUSDT+2.52%LTCUSD+64.72%UNIUSD+5.22%TONUSD+74.91%SUIUSD-0.57%HBARUSDT+0.53%TAOUSDT+2.81%AAVEUSD-0.31%ONDOUSDT-0.55%DOTUSDT-1.75%ICPUSDT-5.75%WLDUSDT-0.52%ARBUSDT-1.10%ATOMUSDT-3.84%INJUSDT-4.42%STXUSDT+2.91%PYTHUSDT+0.50%TIAUSDT-1.31%FETUSDT-3.25%SEIUSDT-1.94%JUPUSDT-4.27%GRTUSDT+0.57%OPUSDT+0.63%IOTAUSDT-1.68%POLUSDT-0.06%WIFUSDT-2.78%AXSUSDT+0.75%EOSUSDT+0.93%IMXUSDT-3.33%FARTCOINUSDT-0.21%GALAUSDT-1.39%DYDXUSDT-3.53%ORDIUSDT-0.23%NOTUSDT-1.52%RONINUSDT+0.62%AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.92%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B+0.02%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA+0.07%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%1816.HK+3.45%HD+0.06%3988.HK-1.13%BAC+0.05%GE0.00%0857.HK-0.49%ORCL-0.01%UNH+0.02%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.14%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%GBPSGD0.00%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%CADJPY0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%CHFJPY0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%EURPLN0.00%NZDMXN0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+2.59%ETHUSD+77.41%USDTUSD+0.10%XRPUSD+64.83%SOLUSD+72.04%TRXUSDT+1.25%ZECUSDT+4.71%XMRUSDT+7.26%DOGEUSD+72.43%LINKUSD+1.21%XLMUSD+1.89%BCHUSDT+2.52%LTCUSD+64.72%UNIUSD+5.22%TONUSD+74.91%SUIUSD-0.57%HBARUSDT+0.53%TAOUSDT+2.81%AAVEUSD-0.31%ONDOUSDT-0.55%DOTUSDT-1.75%ICPUSDT-5.75%WLDUSDT-0.52%ARBUSDT-1.10%ATOMUSDT-3.84%INJUSDT-4.42%STXUSDT+2.91%PYTHUSDT+0.50%TIAUSDT-1.31%FETUSDT-3.25%SEIUSDT-1.94%JUPUSDT-4.27%GRTUSDT+0.57%OPUSDT+0.63%IOTAUSDT-1.68%POLUSDT-0.06%WIFUSDT-2.78%AXSUSDT+0.75%EOSUSDT+0.93%IMXUSDT-3.33%FARTCOINUSDT-0.21%GALAUSDT-1.39%DYDXUSDT-3.53%ORDIUSDT-0.23%NOTUSDT-1.52%RONINUSDT+0.62%

Danaher maps path to faster core growth

NEWS

November 10, 2026 at 00:42 UTC

5 min read
Automated biotech lab machine in use, reflecting Danaher DHR focus on faster AI-driven core growth

Key Points

  • 01Danaher (DHR) targets a shift from mid- to high-single-digit core growth over several years
  • 02Management sets 2027 starting point at 4%–5% core growth, excluding respiratory
  • 03AI investments include an Abcam autonomous lab boosting productivity eightfold
  • 04Company sees $1 billion reshoring upside and long-term Cytiva growth

Danaher outlines multi-year plan to accelerate core growth

Danaher used the UBS Global Healthcare Conference on November 9, 2026, to present a broad plan to lift growth and deepen its position in life sciences and diagnostics. President and CEO Julie Sawyer Montgomery said the company aims to move from mid-single-digit core growth, excluding respiratory products, toward high single-digit growth over the next several years. Management set a 2027 starting point of 4% to 5% core growth and said share gains, new products and better cross-selling could push performance higher.

Montgomery framed the central aim as becoming the defining leader in life sciences and diagnostics, with faster core growth, durable profitability and clear market share gains. She said investors should judge progress over the next five years by higher core growth, visible share gains, competitive wins, innovation and acquisitions.

Growth levers: execution, innovation, talent and capital

To achieve its goals, Danaher is focusing on four main growth levers: commercial execution, innovation, talent and capital allocation. Montgomery wants the company’s operating businesses to coordinate more closely in front of customers, noting that in diagnostics this approach has already created hundreds of millions of dollars in incremental opportunities.

On capital allocation, mergers and acquisitions remain a priority, but only for businesses that fit the Danaher Business System and can offer differentiated growth while helping other operating companies expand. Recent acquisitions Masimo and StatLab were highlighted as part of the innovation pipeline and examples of this strategy in practice.

AI, autonomous science and digital tools

Danaher is investing in artificial intelligence to support autonomous science and drug discovery, though Montgomery said it is too early to quantify the full opportunity. The company has launched its first autonomous laboratory at Abcam, focused on antibodies, and said the facility can increase productivity by eightfold while improving antibody selection for pharma and biopharma customers.

Danaher has also formed partnerships with Anthropic and NVIDIA (NVDA) to support AI-enabled drug discovery tools across instruments, automation, software and consumables. Management views AI-related tools as one of the key near- and medium-term growth drivers, alongside China, Cytiva and diagnostics innovation.

Cytiva, reshoring and bioprocessing outlook

Montgomery reiterated that Cytiva, Danaher’s bioprocessing business, is expected to sustain high-single-digit growth over the long term. She cited biologics, biosimilars, manufacturing reshoring and advanced therapeutic modalities as drivers for this outlook. Cytiva is specified into about 90% of monoclonal antibody volume, a position that can support growth as biosimilars expand access to biologic medicines.

Danaher estimates that manufacturing reshoring represents a $1 billion incremental market opportunity, primarily in bioprocessing equipment and to a lesser extent life sciences instruments. Some orders for expansions of existing facilities are already appearing in the order book, but the company expects most of the revenue opportunity to emerge in 2028 and beyond.

Diagnostics, Masimo integration and innovation pipeline

In diagnostics, Danaher is advancing new platforms and tests, including the full U.S. launch of Beckman Coulter’s DxI 9000 with its associated assays and the development of a neurodegenerative testing portfolio. Cepheid is gaining share and growing at a double-digit rate outside respiratory products, a pace Montgomery believes can continue as new assays launch.

Masimo, one of Danaher’s recent acquisitions, delivered high-single-digit growth in the third quarter and year to date. An initial improvement exercise at Masimo increased productivity in one process by more than 50% while using 50% fewer resources.

Life sciences portfolio and regional trends

Across life sciences, Montgomery cited improving pharma and biopharma markets, while academic and government demand remains below historical levels despite modest sequential improvement. SCIEX delivered high-single-digit growth in the latest quarter, and Beckman Coulter Life Sciences is seeing momentum in liquid handling.

Abcam has grown for three consecutive quarters after Danaher added sales resources, and IDT has grown for two quarters with particular strength in clinical applications. IDT is part of the solution for eight of the 10 largest players in minimal residual disease testing. In China, Danaher’s business grew at a high-single-digit rate in the third quarter, including double-digit growth in biotechnology, mid-single-digit growth in life sciences and growth in diagnostics as customers and channel partners gain confidence under ongoing health care reforms.

Key Takeaways

  • 01Danaher (DHR) is targeting a step-up in core growth, anchored by a 2027 baseline of 4%–5% and a multi-year push toward high-single-digit rates.
  • 02AI-enabled tools, including an autonomous Abcam lab and partnerships with Anthropic and NVIDIA (NVDA), are central to the company’s innovation-led growth strategy.
  • 03Cytiva’s expected high-single-digit long-term growth, a $1 billion reshoring opportunity and Masimo’s integration all underpin Danaher (DHR)’s plan to expand in bioprocessing and diagnostics.

Danaher maps path to faster core growth | Trading Dashboard